newsfilter
← Latest News
GlobeNewswire·

Inhibikase Therapeutics Announces Full Year 2025 Financial Results and Highlights Recent Activity

WILMINGTON, Del., March 26, 2026 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (NASDAQ:IKT) ("Inhibikase" or "Company"), a clinical-stage pharmaceutical company developing therapeutics to modify the course of